Matinas BioPharma (MTNB) Reports In-Line Q4 EPS

Matinas BioPharma (NYSE: MTNB) reported Q4 EPS of ($0.03), in-line with the analyst estimate of ($0.03).

For earnings history and earnings-related data on Matinas BioPharma (MTNB) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• Credo Technology shares rise on analyst support and conference comments
• HP Inc. projects mid-single-digit PC market decline in 2027